Gene therapy has been used in mice to successfully reverse obesity and insulin resistance, as well as other markers of type 2 diabetes, reports a new study. The findings of the study are published in the journal Genome Research.
The obesity epidemic affects nearly half a billion people worldwide, many of them children. Obesity-related diseases, including heart disease, stroke, type 2 diabetes, and cancer, are a leading cause of preventable death. Obesity is caused by both genetic and environmental factors, confounding the development of effective anti-obesity drugs, which exhibit severe off-target effects.
In a study, researchers developed a gene therapy that specifically reduces fat tissue and reverses obesity-related metabolic disease in obese mice.
Researchers used a CRISPR interference system wherein catalytically dead Cas9 protein, and single-guide RNA was targeted to white adipocytes with a tissue-specific fusion peptide. The complex is internalized with little toxicity to the cells, and upon internalization, the molecule complex decreases the expression of Fabp4 and reduces lipid storage in adipocytes. Demonstrating that this delivery method performed well in cells, Chung, and colleagues tested their therapy on obese mice. Mice were fed a diet high in fat leading to obesity and insulin resistance.
Fabp4 repression resulted in a 20% reduction in body weight and improved insulin resistance and inflammation after just six weeks of treatment. Additional systemic improvements were observed, including a reduction in fatty lipid deposition in the liver and reduced circulating triglycerides.
The current standard FDA-approved treatment showed just 5% of body weight loss after one year of treatment in humans. However, while this therapy displays promising results in mice, further studies are required before it can be used in clinical treatment against human disease. Importantly, this work highlights the advances in precision gene-editing technology, which can be translated to other types of therapies.